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Abstract
Background: Neutropenic sepsis remains a common treatment complication for patients receiving systemic anti-
cancer treatment. The UK National Institute for Health and Care Excellence have not recommended switching from
empirical intravenous antibiotics to oral antibiotics within 48 h for patients assessed as low risk for septic
complications because of uncertainty about whether this would achieve comparable outcomes to using
intravenous antibiotics for longer. The UK National Institute for Health Research funded the EASI-SWITCH trial to
tackle this uncertainty.
Methods: The trial is a pragmatic, randomised, non-inferiority trial that aims to establish the clinical and cost-
effectiveness of early switching from intravenous to oral antibiotics in cancer patients with low-risk neutropenic
sepsis. Patients ≥ 16 years, receiving systemic anti-cancer treatment (acute leukaemics/stem cell transplants
excluded), with a temperature of > 38 °C, neutrophil count ≤ 1.0 × 109/L, MASCC (Multinational Association of
Supportive Care in Cancer) score ≥ 21 and receiving IV piperacillin/tazobactam or meropenem for less than 24 h are
eligible to participate. Patients are randomised 1:1 either (i) to switch to oral ciprofloxacin and co-amoxiclav within
12–24 h of commencing intravenous antibiotics, completing at least 5 days total antibiotics (intervention), or (ii) to
continue intravenous antibiotics for at least 48 h, with ongoing antibiotics being continued at the physician’s
discretion (control). Patients are discharged home when their physician deems it appropriate. The primary outcome
measure is a composite of treatment failures as assessed at day 14. The criteria for treatment failure include fever
persistence or recurrence 72 h after starting intravenous antibiotics, escalation from protocolised antibiotics, hospital
readmission related to infection/antibiotics, critical care support or death. Based on a 15% treatment failure rate in
the control group and a 15% non-inferiority margin, the recruitment target is 230 patients.
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Discussion: If the trial demonstrates non-inferiority of early switching to oral antibiotics, with potential benefits for
patient quality of life and resource savings, this finding will have significant implications for the routine clinical
management of those with low-risk neutropenic sepsis.
Trial registration: ISRCTN: 84288963. Registered on the 1 July 2015. https://doi.org/10.1186/ISRCTN84288963.
EudraCT: 2015-002830-35.
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Background
Neutropenic sepsis is a long-recognised and common
complication of systemic anti-cancer treatment (SACT)
[1]. The term broadly refers to a significant inflamma-
tory response to a presumed bacterial infection in a per-
son with or without fever and a low blood neutrophil
count [2]. Despite the widespread adoption of prophy-
lactic colony-stimulating factors (CSF) and fluoroquino-
lone antibiotics for patients at high risk of septic
complications, neutropenic sepsis remains potentially life
threatening. Significant patient morbidity can also occur
through hospitalisation and associated dose delays and
reductions to planned SACT [2, 3].
Neutropenic sepsis continues to be viewed as a time-
critical medical emergency, with widespread agreement
that early recognition and prompt administration of
broad-spectrum empirical antibiotics are essential to
successful treatment [2, 4–6]. However, much less con-
sensus exists on the optimal patient management there-
after, including when to switch from intravenous (IV) to
oral antibiotics and the duration of antibiotic treatment
and hospital admission. Widely variable practice has
been noted among cancer centres in the United King-
dom [7].
A spectrum of neutropenic sepsis severity exists, encom-
passing a heterogeneous group of patients with variable
prognoses [8]. Some patients can quickly deteriorate and
develop septic shock from overwhelming infection, for
whom ongoing inpatient IV antibiotics with goal-directed
resuscitation is critical. At the other end of the spectrum
are patients who do not demonstrate clear clinical or
microbiological evidence of proven infection, have un-
complicated hospital admissions and are at low risk of de-
veloping septic complications. These patients potentially
receive overtreatment, with the associated distress of hos-
pitalisation and additional burden to the healthcare system
[9]. Risk stratification tools have therefore been developed
in an attempt to identify patients predicted to be at low
risk of an adverse outcome. The Multinational Association
of Supportive Care in Cancer (MASCC) score is the most
widely validated risk score for SACT-induced neutropenic
sepsis [2, 5, 6, 10] (Table 1).
A Cochrane review of oral versus IV antibiotics for
neutropenic sepsis, evaluating 22 trials, concluded that
significant differences are unlikely to exist in treatment
failure or mortality rates between oral antibiotic and IV
antibiotic strategies. Most studies did not utilise any for-
mal risk stratification tools but excluded high-risk pa-
tients with acute leukaemia, haemodynamic instability,
evidence of organ failure or localising signs of infection.
The Cochrane review therefore broadly supported the
early use of oral antibiotics in low-risk neutropenic sep-
sis but noted that most trials were small in sample size,
often were single centre and had methodological con-
cerns. Therefore, a robust recommendation for upfront
or early oral antibiotic therapy could not be made [11].
Guidance issued in 2012 by the UK National Institute
for Health and Care Excellence (NICE) recommends
that switching to oral antibiotics should be considered in
patients deemed at low risk of complications after 48 h
of IV therapy. This guidance was based on limited evi-
dence supporting the switch to oral antibiotics in low-
risk patients but with no consistent time point identified,
leading to NICE being unable to recommend an oral
switch before 48 h. The NICE guideline development
group (GDG) noted that switching at an earlier time
point (for example, at 8–16 h) may be beneficial for pa-
tients and hospital resource use but that no meaningful
evidence currently exists to support this approach [2].
Current European guidelines suggest that after the initial
patient assessment, including the prompt institution of
Table 1 Multinational association of supportive care in cancer
risk index (adapted from Klastersky (2000)) [10]
Characteristic Weight
Burden of febrile neutropenia: no or mild symptomsa 5
Burden of febrile neutropenia: moderate symptomsa 3
No hypotension (systolic blood pressure > 90 mmHg) 5
No chronic obstructive pulmonary disease 4
Solid tumour or no previous fungal infection 4
No dehydration requiring parenteral fluids 3
Outpatient status 3
Age < 60 years 2
The maximum theoretical score is 26
A score of ≥ 21 suggests a low risk of a serious medical complication,
including organ failure, critical care support or death
aPoints attributable to the variable ‘burden of febrile neutropenia’ are
not cumulative
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empirical broad-spectrum antibiotics, inpatient oral anti-
biotic treatment may be suitable for patients identified
as low risk. However, they note that many clinicians pre-
fer to continue IV treatment for at least 48 h and then
consider a change to oral antibiotics if the fever resolves
[5].
The NICE GDG also reviewed the evidence for in-
patient versus outpatient management of neutropenic
sepsis and concluded that outpatient management can
be considered for selected low-risk patients, taking into
account their individual clinical and social circum-
stances. Although the meta-regression undertaken by
the GDG suggested that early discharge (before 24 h)
may be associated with an increased likelihood of re-
admission or therapy change, the quality of evidence
supporting outpatient management was low to moder-
ate. The available data were limited by a lack of report-
ing of key outcomes such as critical care admission or
clinically documented infection and a very low event rate
for adverse outcomes including death [2]. Similarly, the
literature relating to the impact on the quality of life for
different models of care, including immediate use of oral
antibiotics and non-admission to hospital, is negligible,
with a single study suggesting that role function im-
proved more for inpatients than for home care patients
but that emotional function declined with hospital ad-
mission [12]. Therefore, if a short period of hospital ad-
mission was found to be safe and effective for selected
patients with neutropenic sepsis, this approach could
provide considerable improvements in quality of life and
health resource usage.
NICE therefore recommended that a randomised trial
should be undertaken to evaluate the effectiveness of
stopping IV antibiotics or switching to oral antibiotics
within the first 24 h of treatment in patients receiving IV
antibiotics for neutropenic sepsis. The early switch to
oral antibiotic therapy in patients with low-risk neutro-
penic sepsis (EASI-SWITCH) trial was developed in re-
sponse to this recommendation and to a commissioned
call from the UK National Institute of Health Research
(NIHR) Health Technology Assessment (HTA)
programme to address this evidence gap. It aims to es-
tablish the clinical and cost effectiveness of an early
switch to oral antibiotics 12–24 h after IV antibiotic
treatment commences in low-risk cancer patients with
neutropenic sepsis.
Study hypothesis and objectives
An early switch to oral antibiotic therapy, 12–24 h after
IV antibiotic treatment commences in low-risk cancer
patients with neutropenic sepsis, is hypothesized as non-
inferior to standard care. The primary objective is to de-
termine whether an early switch to oral antibiotic ther-
apy is non-inferior to current standard care of IV
antibiotics for at least 48 h in terms of treatment failure.
Treatment failure is defined by a composite measure in-
corporating a number of important clinical outcomes
assessed at day 14.
A number of secondary objectives are included to as-
sess the impact of an early switch to oral antibiotics on
patients and the health service. Secondary objectives are
(i) short-term change in health-related quality of life, (ii)
treatment cost-effectiveness, (iii) time to fever resolution
from initial IV antibiotic administration, (iv) adverse
events related to the antibiotics, (v) total length of hos-
pital stay, (vi) readmission to hospital within 28 days,
(vii) death within 28 days, (viii) adjustment to subse-
quent scheduled cycle of chemotherapy within 28 days
and (ix) patient preference for antibiotic treatment strat-
egy. As an exploratory objective, whole blood, serum
and plasma samples are also being collected for the fu-
ture analysis of potential biomarkers, which may en-
hance neutropenic sepsis risk stratification and
management.
Methods/Design
Study design
A pragmatic, randomised, open-label, non-inferiority
trial has been designed to compare the early switch to
oral antibiotics, 12–24 h after IV antibiotic treatment
commences, versus standard care, which comprises IV
treatment for at least 48 h, in cancer patients with neu-
tropenic sepsis at low risk of complications (Fig. 1). The
EASI-SWITCH trial is funded by the UK NIHR HTA
programme, sponsored by the Belfast Health and Social
Care Trust and supported by the Northern Ireland Clin-
ical Trials Unit (NICTU). The study protocol (most re-
cently Version 8.0, 21 June 2018) was developed and
implemented in accordance with the Consolidated Stan-
dards of Reporting Trials (CONSORT) 2010 statement
[13] and the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) 2013 checklist [14], as
provided in Additional file 1.
Study setting
Participants are recruited from NHS cancer centres and
units across England, Scotland, Wales and Northern
Ireland, to ensure that the sample is broadly representa-
tive of patients developing neutropenic sepsis across the
United Kingdom. A list of sites can be obtained from the
NICTU.
Eligibility criteria
Eligibility is determined by the inclusion and exclusion
criteria listed in Table 2. Patients enrolled in other Phase
I Investigational Medicinal Product (IMP) studies and
other antimicrobial IMP studies are excluded. Patients
enrolled in other Phase II-IV IMP or observational
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studies are potential candidates for this study if the bur-
den of participating is not expected to be too onerous.
Based on NICE guidance, all patients enrolled have
already been commenced on standard dose IV piperacil-
lin/tazobactam or meropenem as initial antibiotic treat-
ment, in accordance with the local neutropenic sepsis
policy and the summary of product characteristics for
these antibiotics.
Standard care (control arm)
Participants in the standard care group are allocated to
continue treatment with IV antibiotics for a minimum of
48 h. This was selected based on the NICE guidance rec-
ommendations [2]. Subsequent antibiotic management is
at the discretion of the treating physician, who may switch
to oral antibiotics or stop antibiotics at any point there-
after, thereby reflecting the variation encountered in rou-
tine clinical practice [7].
Early oral antibiotic switch (intervention arm)
Participants randomised to the intervention group
switch from IV antibiotic treatment within 12–24 h of
starting, to co-amoxiclav 625mg three times daily and
ciprofloxacin 750 mg twice daily, to complete at least 5
days of antibiotic treatment in total. The timepoint of
the oral switch is defined as the time at which the final
dose of IV antibiotic is administered. The combination
of a quinolone and a second drug active against gram-
Fig. 1 Study schematic diagram
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positive bacteria (e.g., co-amoxiclav) was based on the
conclusions of the Cochrane review [11].
Use of CSFs as treatment for the episode of neutro-
penic sepsis is prohibited in both intervention groups.
Prophylactic CSF is not an exclusion criterion if pre-
scribed routinely as an integral component of a specific
SACT regimen. Any other additional treatments or
investigations that patients require are as per standard
care. Escalation from protocol-specified antibiotic treat-
ment might be required if evidence emerges of clinical
deterioration, progression of the presumed infection, a
microbiologic indication based on positive cultures or an
adverse reaction to the prescribed antibiotics. A change
from protocol-specified antibiotics, including additional
antibiotic treatment other than the study drugs or per-
sistent/recurrent fever (> 38 °C) after 72 h is within the
definition of treatment failure, with such participants
reaching the trial’s primary endpoint.
Patients are discharged home from hospital when their
treating physician is content to do so, with a patient
diary to record any further temperatures and oral anti-
biotic compliance. Due to the pragmatic nature of the
trial, specific discharge criteria have not been protoco-
lised, but clinicians are assumed to take into consider-
ation the patient’s overall clinical condition and psycho-
social circumstances, as per their normal clinical
practice.
The oral and IV study antibiotics (oral ciprofloxacin
and co-amoxiclav and IV piperacillin/tazobactam and
meropenem) are regarded as IMPs by the Medicines and
Healthcare products Regulatory Agency (MHRA) for the
purposes of this trial. EASI-SWITCH has been desig-
nated a Type A study with no higher risk than the risk
of standard medical care, and therefore, as all are UK li-
censed drugs, routine hospital stock is being used, sup-
plied and labelled in accordance with usual clinical
practice.
Primary outcome measure
The primary outcome measure of treatment failure is
assessed at day 14. This composite measure is defined by
the presence of any one of (i) persistence or recurrence
of fever (temperature > 38 °C) after 72 h of IV antibiotic
initiation, (ii) physician-directed escalation from
protocol-specified antibiotic treatment, (ii) re-admission
to hospital (related to infection or antibiotic treatment),
(iv) admission to critical care or (iv) death.
A core outcome set is unfortunately lacking for neu-
tropenic sepsis. The constituents of our composite were
determined from the NIHR commissioning brief, inter-
national expert consensus guidelines [15, 16, 17], other
large neutropenic sepsis reported trials [18] and feed-
back from patient representatives and co-investigators
on outcomes that are important to patients.
Secondary outcome measures
A number of secondary outcome measures address the
secondary objectives as described above and have been
selected to support the assessment of the clinical and
cost-effectiveness of an early oral antibiotic switch. The
following are assessed on day 14:
Table 2 Current trial eligibility criteria
Eligibility criteria
Inclusion criteria
(i) Age over 16 years
(ii) Receiving SACT for a cancer diagnosis
(iii) Started on empirical IV piperacillin/tazobactam or
meropenem, for suspected NS, for less than 24 h. Patients
who have been started on additional antimicrobial drugs
(e.g., gentamicin or teicoplanin) are eligible, provided the
physician in charge of their care is willing to stop this
additional antimicrobial at the time of enrolment
(iv) Absolute neutrophil count ≤ 1.0 × 109/L with either a
Temperature of at least 38 °C or
Other signs or symptoms consistent with clinically significant
sepsis, e.g., hypothermia.
Self-measurement at home or earlier hospital assessment of
temperature are acceptable provided this is documented in
the medical notes and is within 24 h prior to IV antibiotics
administration.
(v) Expected duration of neutropenia < 7 days
(vi) Low risk of complications using a validated risk score (MASCC
≥ 21)
(vii) Able to maintain adequate oral intake and take oral
medication
(viii) Adequate hepatic (AST+/ALT < 5x upper limit of normal
(ULN)) and renal function (serum creatinine < 3x ULN) within
the 24 h prior to randomisation
(ix) Physician in charge of care willing to follow either the
intervention or standard care protocol per randomisation, at
enrolment, including not treating with colony-stimulating
factor (CSF). Prophylactic use of CSF is not an exclusion cri-
teria if prescribed routinely as an integral component of a
specific SACT regimen.
Exclusion criteria
(i) Underlying diagnosis of acute leukaemia or haematopoietic
stem cell transplant
(ii) Hypotension (systolic pressure < 90 mmHg or reduction of >
40 mmHg from known baseline on > 1 measurement) within
the 24 h prior to randomisation
(iii) Prior allergy, serious adverse reaction, or contraindication to
any study drug
(iv) Enrolled in the trial with prior episode of neutropenic sepsis
(v) Previously documented as being colonised with an organism
resistant to a study drug regimen, e.g., MRSA (methicillin-
resistant Staphylococcus aureus)
(vi) Localising signs of severe infection (pneumonia, soft tissue
infection, central venous access device infection, presence of
purulent collection)
(vii) Patient unable to provide informed consent
(viii) Pregnant or breastfeeding women
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(i) Time to resolution of fever from initial IV antibiotic
administration
(ii) Adverse events due to antibiotics or their route of
administration
(iii)Hospital resource utilisation, including the length of
hospitalisation
(iv)Health-related quality of life (based on the EQ-5D-
5 L measurement tool and compared with EQ-5D-5
L from baseline) [19]
(v) Cost-effectiveness. The cost- effectiveness analysis,
consistent with the primary outcome measure, will
be performed to estimate the cost per treatment
failure avoided at 14 days, and a cost-utility analysis
will estimate the cost per quality-adjusted life year
(QALY) at 14 days.
(vi) Patient preferences for antibiotic treatment (using a
trial specific discrete choice questionnaire based on
a previously published neutropenic sepsis study in
haematological malignancy) [20].
Further secondary outcomes, comprising readmission
to hospital (related to infection or antibiotic treatment),
change in subsequent planned SACT and death, are also
assessed on day 28.
Participant timeline
Two follow-up reviews occur with a research nurse, by
telephone if convenient, at day 14 and day 28. At day 14,
the primary outcome measure data are collected with
patients assessed for evidence of treatment failure. Pa-
tients complete two short questionnaires for health-
related quality of life (EQ-5D-5 L) and antibiotic treat-
ment preference (trial-specific patient follow-up ques-
tionnaire) and review their completed diaries. A shorter
review at day 28 captures survival status, adverse events,
hospital admissions and the impact of the neutropenic
sepsis episode on their next SACT cycle (if applicable).
A summary schedule of assessments is detailed in
Table 3.
Sample size
The target sample size is 230 patients. This is based on
an assumed 15% treatment failure rate in the standard
care arm and 15% non-inferiority margin, at 90% power
(one-sided 97.5% confidence intervals (CI)), which re-
quires 98 patients per group. A 5% dropout rate and
10% crossover from the control to intervention group
have also been accounted for, resulting in the target of
115 participants per group (230 in total).
The assumed 15% treatment failure rate for patients
receiving standard care was derived from the three stud-
ies thought to best reflect the proposed control arm in
relation to the populations included and the duration of
the IV antibiotic treatment administered [20–22].
Selecting the non-inferiority margin was challenging
due to the limited evidence available to help guide this
selection. A 10% non-inferiority margin was originally
chosen to reflect the recommendations from a historic
consensus guideline for neutropenic antibiotic trials [15].
This guidance relates to the overall neutropenic sepsis
population but with no consideration for stratification
by risk of septic complications and therefore may be
overly simplistic given the significant differences in clin-
ical outcomes of ineffective treatment in low- and high-
risk patients. The trial’s target population are patients at
low risk of septic complications and are selected through
their MASCC score and additional study eligibility cri-
teria. Treatment failure in this low-risk population, as
highlighted in the Cochrane review, therefore typically
results in persistence or recurrence of fever, leading to
prolongation of admission or readmission for further IV
antibiotic treatment, with no association noted between
mortality and oral antibiotic treatment in low-risk pa-
tients [11]. Given that the study population were pa-
tients with neutropenic sepsis at low risk of
complications, UK oncologists and patient representa-
tives were surveyed and supported increasing the non-
inferiority margin from 10 to 15%. Respondents noted
that, even if the treatment fails for up to an extra 15 per
100 patients as a result of the intervention (in addition
to the expected 15 treatment failures), this would be
greatly outweighed by the advantage of 70 patients hav-
ing successful oral treatment, often at home.
Recruitment
Patients commenced on IV antibiotics for neutropenic
sepsis at each study site are screened daily for eligibility
within 24 h of starting the IV treatment. Informed con-
sent is obtained from each participant by trained re-
search staff (Additional files 2 and 3). Consent also is
sought for the blood samples to be taken, stored and
analysed for this study and for future ethically approved
research. Consideration has been given to the short win-
dow for patients to consider trial participation and pro-
vide informed consent and strategies taken to raise trial
awareness at the sites, which include displaying patient
information posters in clinical areas and making a short
patient information sheet available to patients at high
risk of neutropenic sepsis.
Randomisation and allocation concealment
Eligible patients are randomised using an automated sys-
tem, with randomly permuted blocks, 1:1 to the inter-
vention and standard care groups. This use of an
automated randomisation system and restricting access
to the randomisation sequence to only the trial statisti-
cian ensures that allocation concealment is maintained.
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Blinding
Due to the pragmatic nature of this trial, participants, care
providers and the research team are not blinded to the al-
located treatment. Furthermore, patient representatives
advised that participants were highly likely to reveal their
treatment allocation to outcome assessors, and therefore,
any attempt to blind this group would also be subverted.
Data collection methods and management
Trial data, including study specific worksheets, patient
diaries and the two patient questionnaires (EQ-5D-5 L
and patient antibiotic treatment preference question-
naire) are entered onto a web-based case report form on
a clinical trial database (MACRO) by delegated site
personnel. Data are processed as per the study specific
Table 3 Schedule of assessments
Study period
Day 0 Study visits and
procedures
Pre-consent
(standard
care)
Pre-
randomisation
Randomisation Day
1–2
Day
3–5
Day
6–14
Day
28
Pre-consent eligibility screening
Eligibility screening as appropriate (as per standard care), e.g., ANC, AST/
ALT, creatinine, blood culture. When available, Hb, platelets, CRP, albumin,
lactate
X
Informed consent
Informed consent obtained x
Pre-randomisation eligibility and assessments
Eligibility screening as appropriate (non-standard care) e.g., pregnancy
test, MASCC score, max temp prior to randomisation, signs/symptoms of
sepsis
x
EQ-5D-5 L x
Randomisation
Standard care antibiotic administration X x x x x
Intervention (early switch) antibiotic administration (IV antibiotics will
commence prior to informed consent)
X x x x x
Research blood sample x
GP letter sent x
Baseline assessments to be completed on CRF after eligibility is confirmed
Demographics, vital signs, cancer, medical and SACT history, hospital
admission details
x
Concomitant medications x x x x x
Relevant microbiological results x x x x x
Daily data collection
Antibiotic regimen X x x x x x
Highest daily temperature (whilst inpatient or temperature recorded if
unwell as an outpatient)
X x x x x x
Protocol compliance
Adherence to protocol specified intervention x x
Patient follow-up
Survival status x x
EQ-5D-5 L x
Patient follow-up questionnaire x
New medications x x
Changes to next planned SACT cycle x
Hospital discharge/re-admission/critical care admission details x x
Recording and reporting of adverse events x
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data management plan. Patient confidentiality is main-
tained with patients only identified by their assigned
unique trial identifier and initials, and all databases are
password protected. On-site monitoring visits are con-
ducted by NICTU in accordance with the trial monitor-
ing plan at each site, from the time of site initiation until
close-out. Compliance with the protocol and the imple-
mented amendments is carefully reviewed. All protocol
amendments to date have received the appropriate regu-
latory and ethical approvals prior to electronic dissemin-
ation to investigators with appropriate training provided
by NICTU.
Proposed statistical analyses
An intention to treat analysis (regardless of protocol ad-
herence) as well as a per protocol analysis (involving
only those patients completing their originally allocated
treatment) will be conducted. Non-inferiority of early
switch will only be proven if it is demonstrated in both
analyses, to minimize the risk of bias wrongly conclud-
ing non-inferiority. Analyses will be one-sided and at a
significance level of 0.05. The difference in treatment
failure rate (95% CI) will be compared to the non-
inferiority margin of 15%. As this is a non-inferiority
trial, the null hypothesis is that the degree of inferiority
of the intervention to the control (standard care) is
greater than the non-inferiority margin of 15%. The al-
ternative hypothesis is therefore that the intervention is
inferior to the control by less than the non-inferiority
margin of 15%. Therefore, non-inferiority would be
established by showing that the upper bound of a one-
sided 95% CI for control-intervention does not exceed
15%.
Exploratory subgroup analyses will be reported using
99% CI. Logistic regression will be used with interaction
terms for the following subgroups: (i) tumour type (solid
tumour vs. lymphoma), (ii) neutrophil count at random-
isation (≤ 0.5 × 109/L vs. 0.5–1.0 × 109/L) and (iii) max-
imum temperature at randomisation (< 38 °C vs. ≥
38 °C).
Baseline characteristics, follow-up measurements and
safety data will be described using appropriate descrip-
tive summary measures. A within-trial economic evalu-
ation will be performed to assess the cost-effectiveness
of an early switch to oral antibiotics compared with
standard care. A cost-effectiveness analysis consistent
with the primary outcome measure will be carried out to
estimate the cost per treatment failure avoided at day 14
and a cost utility analysis will estimate the cost per
QALY at day 14.
Monitoring
A number of oversight committees have been estab-
lished for EASI-SWITCH. These include a Trial
Management Group, responsible for the day-to-day op-
erational management and a Trial Steering Committee,
of which 75% of the members are independent from the
trial team, providing overall supervision of the trial’s
progress. An independent Data Monitoring and Ethics
Committee (DMEC) comprises experts in the field and
is monitoring the overall conduct of the trial as well as
relevant data, ensuring that the rights, safety and well-
being of trial participants are being safeguarded. The
DMEC charter details the terms of reference of the
DMEC, including membership and responsibilities, and
is available from the NICTU. Only adverse reactions (ad-
verse events related to the administration of study drugs)
and serious adverse events are currently being recorded
and reported. All deaths occurring within 28 days of ran-
domisation will be reported as a serious adverse event
regardless of the underlying pathology. No specific post-
trial provisions have been made for the participants. The
sponsor provides indemnity for any negligent harm
caused to patients by the design of the trial protocol
through the Clinical Negligence Fund in Northern
Ireland. The study will be stopped early if recommended
by the Trial Steering committee, sponsor, regulatory au-
thorities or research ethics committee.
Dissemination
The study findings will be published in international
peer-reviewed journals and presented at both national
and international meetings and to appropriate patient
groups, with authorship granted to those who have made
a substantive intellectual contribution to the study. Re-
quests for data sharing will be reviewed on an individual
basis by the chief investigators and trial management
group.
Discussion
SACT use continues to rise steadily, and therefore, neu-
tropenic sepsis will likely continue to represent a com-
mon and potentially life-threatening treatment
complication for cancer patients. NICE guidance in 2012
provided the first UK consensus guideline, providing ro-
bust evidence-based recommendations aimed at unifying
and improving neutropenic sepsis practice, but import-
antly, this guidance also highlighted a number of out-
standing questions regarding optimal management.
NICE were unable to recommend switching from empir-
ical IV to oral antibiotics at less than 48 h in low-risk pa-
tients because of the uncertainty about whether this
achieved comparable outcomes to current standard
practice of longer IV antibiotics [2]. To bridge this evi-
dence gap, the EASI-SWITCH trial commissioned by
the UK NIHR aims to provide a definitive randomised
trial evaluating an early oral switch in low-risk neutro-
penic sepsis patients.
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The EASI-SWITCH trial was designed with the
intention of delivering a rigorous but highly pragmatic
trial, which will accurately assess the effectiveness of
an early oral switch in routine clinical practice. The
generalisability of the trial’s results and their potential
to inform clinician practice and neutropenic sepsis
policies has been a priority during protocol develop-
ment. The trial team acknowledges that, even with
the introduction of NICE guidance, variation remains
in local neutropenic sepsis policies and clinicians’ in-
dividual practices throughout the UK with respect to
criteria for diagnosing neutropenic sepsis, routine use
of risk stratification tools and approaches to antibiotic
management and hospital admission. Whilst most
centres and clinicians have retained a cautious ap-
proach, which reflects the current NICE guidance,
some have embraced novel strategies to stratify risk
and manage low-risk patients on oral antibiotics as
outpatients.
The trial’s eligibility criteria and protocolised treat-
ment in the standard care (control) group aim to best
reflect the management of the majority of low-risk
patients being commenced on a neutropenic sepsis
treatment pathway in routine practice and the treat-
ment they receive. Apart from protocolising the mini-
mum requirements for IV antibiotics in the control
group and the oral antibiotic intervention, we have
strived to give physicians flexibility with all other as-
pects of patients management, including ongoing anti-
biotic and discharge decisions, as would be occurring
in routine practice. The outcomes have also been
carefully selected to focus on those issues most rele-
vant to patients and clinicians for experiencing and
delivering high quality, safe and effective neutropenic
sepsis care. This has resulted in as pragmatic a trial
design as possible, which aims to address some of the
previous limitations of trials in this field and provide
results that will be generalisable to the majority of
UK practice and therefore help inform routine clinical
care and policies across the NHS.
An internal pilot study preceded the main trial, with
the main parameters of interest being recruitment
rates, adherence to the protocol-specified intervention
and separation in terms of timing of the antibiotic
switch between the two intervention groups. The pilot
phase involved four sites and lasted 9 months. Adher-
ence to the protocol-specified intervention in both
intervention groups was acceptable (> 75%), and ad-
equate separation existed between the groups, in
terms of the timing of the antibiotic switch being at
least 24 h between them. On the other hand, recruit-
ment rates were lower than anticipated. Adjustments
were therefore made to the eligibility criteria to align
even more fully with NICE guidance and clinical
practice. This included broadening the diagnostic cri-
teria for neutropenic sepsis, definitions for liver dys-
function and hypotension and permitting recent
prophylactic antibiotic use. The adjusted eligibility cri-
teria positively impacted recruitment, and we pro-
ceeded to the main trial, expanding the number of
participating sites. However, an overall downward
trend in neutropenic sepsis admissions at sites re-
sulted in the target recruitment rate per site being
lowered and the number of recruiting sites being fur-
ther increased. An adjustment to the non-inferiority
margin and therefore sample size was also undertaken
as described above to ensure delivery of a clinically
meaningful study.
If EASI-SWITCH meets its primary outcome, dem-
onstrating that an early switch to oral antibiotics in
low-risk patients with neutropenic sepsis is non-
inferior to current treatment, it will provide evidence
for an early oral switch as a management strategy for
such patients. Treatment of low-risk neutropenic sep-
sis based on oral therapy could bring advantages for
both patients and the NHS. Such an approach could
be expected to provide quality of life benefits for pa-
tients, with improved convenience from a shorter
length of hospital stay and less IV access complica-
tions, including infection. Potential resource benefits
also exist for healthcare services by reducing health-
care utilisation, including drug costs, aseptic prepar-
ation and administration time, as well as inpatient
treatment costs.
Trial status
Recruitment to the initial pilot study commenced
February 2016. At the time of the initial journal sub-
mission, (October 2019), recruitment was ongoing
across 15 UK sites using protocol version 8 (21 June
2018). At the end of November 2019, a decision was
taken to halt recruitment to the trial based on a
DMEC recommendation to stop on the grounds of
slow recruitment. No safety concerns existed to con-
tinue protocol-directed therapy and follow-up of all
enrolled patients, with a current plan for database
lock in May 2020.
The EASI-SWITCH team can be contacted at the
Northern Ireland Clinical Trials Unit at EASI-
SWITCH@nictu.hscni.net.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04241-1.
Additional file 1. SPIRIT checklist.
Additional file 2. Patient information sheet.
Additional file 3. Patient consent form.
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